176 related articles for article (PubMed ID: 37229799)
1. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review.
Tolaymat S; Sharma K; Kagzi Y; Sriwastava S
Mult Scler Relat Disord; 2023 Jul; 75():104763. PubMed ID: 37229799
[TBL] [Abstract][Full Text] [Related]
2. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
3. Neutropaenia complications from Ocrelizumab and Rituximab treatment.
Pang V; Seery N; Wesselingh R; Yeh W; Zhong M; Tan T; Dwyer C; Nesbitt C; Rath L; Perera D; Bridge F; Skibina O; Bosco JJ; Jokubaitis V; Marriott M; Butkueven H; Van Der Walt A; Massey J; Sutton I; Monif M
Mult Scler Relat Disord; 2024 Jan; 81():105147. PubMed ID: 38043368
[TBL] [Abstract][Full Text] [Related]
4. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
Boldrini VO; Mader S; Kümpfel T; Meinl E
Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
6. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.
Lieb S; Heni M; Rauschenberg S; Lange K; Feisthammel J; Bläker H; Wiegand J
Z Gastroenterol; 2023 Nov; 61(11):1500-1503. PubMed ID: 36736346
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
10. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
12. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
14. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
Delgado SR; Faissner S; Linker RA; Rammohan K
J Neurol; 2024 Apr; 271(4):1515-1535. PubMed ID: 37906325
[TBL] [Abstract][Full Text] [Related]
15. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
16. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
Carlson AK; Amin M; Cohen JA
Drugs; 2024 Mar; 84(3):285-304. PubMed ID: 38480630
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
Cotchett KR; Dittel BN; Obeidat AZ
Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
Sellebjerg F; Blinkenberg M; Sorensen PS
CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated colitis associated with ocrelizumab: A new safety risk.
Kim T; Brinker A; Croteau D; Lee PR; Baldassari LE; Stevens J; Hughes A; Tomaino J; deFonseka A; Altepeter T; Kortepeter CM
Mult Scler; 2023 Sep; 29(10):1275-1281. PubMed ID: 37706451
[TBL] [Abstract][Full Text] [Related]
20. Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis.
Challa B; Esnakula AK
Histopathology; 2024 Apr; 84(5):765-775. PubMed ID: 38114289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
